Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Fallopian Tube Neoplasms 7Ovarian Neoplasms 6Colorectal Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 4Melanoma 4Carcinoma, Hepatocellular 4Lymphoma, Large B-Cell, Diffuse 3Glioblastoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Brain Neoplasms 3Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Lymphoid Interstitial Pneumonia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Burkitt Lymphoma 2Brenner Tumor 2Breast Neoplasms 2

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Breast Carcinoma × Disulfides × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡